首页> 美国卫生研究院文献>Rheumatology Advances in Practice >The therapeutic efficacy of denosumab for the loss of bone mineral density in glucocorticoid-induced osteoporosis: a meta-analysis

【2h】

The therapeutic efficacy of denosumab for the loss of bone mineral density in glucocorticoid-induced osteoporosis: a meta-analysis

机译：地诺单抗治疗糖皮质激素引起的骨质疏松症中骨矿物质密度降低的疗效：一项荟萃分析

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

摘要
著录项
相似文献
相关主题

摘要

Prevention of steroidal osteoporosis is an important issue. There is no clear consensus on the impact of anti-RANKL antibody (denosumab) on BMD in patients with glucocorticoid-induced osteoporosis (GIO). In this study, we aimed to evaluate the impact of denosumab on BMD loss in patients with GIO.

机译：预防类固醇骨质疏松是一个重要的问题。对于糖皮质激素诱导的骨质疏松症（GIO）患者，抗RANKL抗体（denosumab）对BMD的影响尚无明确共识。在这项研究中，我们旨在评估地诺单抗对GIO患者BMD丢失的影响。

著录项

期刊名称 Rheumatology Advances in Practice
作者
Yuta Yamaguchi; Takayoshi Morita; Atsushi Kumanogoh;
展开▼
作者单位

展开▼
年(卷),期 2020(4),1
年度 2020
页码 -1
总页数 10
原文格式 PDF
正文语种
中图分类免疫性疾病;
关键词
denosumab; glucocorticoid-induced osteoporosis; bone mineral density; meta-analysis; anti-RANKL antibody;

机译：地诺单抗;糖皮质激素诱导的骨质疏松症;骨矿物质密度;元分析;抗RANKL抗体;

相似文献

外文文献
中文文献
专利

1. Significant improvement of bone mineral density by denosumab without bisphosphonate pre-treatment in glucocorticoid-induced osteoporosis [J] . Suzuki Takako, Nakamura Yukio, Kato Hiroyuki Modern rheumatology . 2018,第5期

机译：Deaosumab的骨矿物质密度的显着改善，没有双膦酸盐在糖皮质激素诱导的骨质疏松症中的预处理
2. Effects of ginsenoside Rg3 on bone loss, bone mineral density and osteoclast number in glucocorticoid-induced osteoporosis rats, and the likely mechanism of action [J] . Maoxiu Peng, Gangyi Jiang, Shaoqi He, Tropical Journal of Pharmaceutical Research . 2020,第4期

机译：人参皂苷RG3对糖皮质激素诱导的骨质疏松大鼠骨质损失，骨密度和骨细胞数的影响，以及可能的作用机制
3. Safety of denosumab in postmenopausal women with osteoporosis or low bone mineral density: a meta-analysis [J] . Zhenyu Zhou, Chen Chen, Jun Zhang, International Journal of Clinical and Experimental Pathology . 2014,第5期

机译：地诺单抗在绝经后骨质疏松或骨密度低的女性中的安全性：一项荟萃分析
4. Synthetic Bone Mineral (SBM) for Osteoporosis Therapy: Part 1 - Prevention of Bone Loss from Mineral Deficiency [C] . Racquel Z. LeGeros, Dindo Mijares, Fang Yao, Bioceramics . 2008

机译：骨质疏松症治疗用合成骨矿物质（SBM）：第1部分-预防因矿物质缺乏引起的骨丢失
5. Osteoporosis: Identification of factors associated with fracture, bone mineral density, bone geometry and bone strength in older adults [D] . Barbour, Kamil. 2010

机译：骨质疏松症：确定与老年人骨折，骨矿物质密度，骨几何形状和骨强度有关的因素
6. Long-term follow up after denosumab treatment for osteoporosis – rebound associated with hypercalcemia parathyroid hyperplasia severe bone mineral density loss and multiple fractures: a case report [O] . Yves Maugars, Pascale Guillot, Joëlle Glémarec, 2020

机译：骨质疏松症治疗后的长期跟进 - 与高钙血症甲状旁腺增生严重骨矿物密度损失和多重骨折相关的反弹：案例报告
7. Effects of ginsenoside Rg3 on bone loss, bone mineral density and osteoclast number in glucocorticoid-induced osteoporosis rats, and the likely michanism of action [O] . Maoxiu Peng, Gangyl Jiang, Shaoqi He, 2020

机译：人参皂苷RG3对糖皮质激素诱导的骨质疏松症大鼠骨质损失，骨密度和骨质体数的影响，以及米科的行动可能

The therapeutic efficacy of denosumab for the loss of bone mineral density in glucocorticoid-induced osteoporosis: a meta-analysis

摘要

著录项

相似文献

相关主题

期刊订阅